Introduction. The aim of this study was to investigate the attitude (view, likely uptake and preferred strategy) towards cell-free fetal DNA (cfDNA) testing among pregnant women before a first-trimester risk assessment for trisomy 21 (unselected women) and after obtaining a high risk. Material and methods. Unselected and high-risk women attending first-trimester screening (Rigshospitalet, Copenhagen University Hospital) were invited to fill out the questionnaire Antenatal testing for Down syndrome as an online survey. Results. The survey included 203 unselected and 50 high-risk women (response rates of 74.8% and 84.7%, respectively). Nearly all considered cfDNA testing a positive development in antenatal care, and 97.2% would like it to be offered. Offering cfDNA testing as an alternative to invasive testing would increase the uptake of follow-up testing compared with invasive testing alone (98.8% vs. 90.7%, p < 0.001). Women who would only accept follow up by cfDNA testing were more likely to continue an affected pregnancy (30.0% vs. 3.6%, p < 0.001) or have doubts about termination (50.0% vs. 32.1%, p < 0.001). Conclusions. Offering cfDNA testing would likely increase the uptake of followup testing without a corresponding rise in the termination rate of affected fetuses as some women test for information only. However, both unselected and high-risk women had overwhelmingly positive views underlining attention to avoid routinization.
Introduction
Screening for trisomy 21 (T21) with analysis of cell-free fetal DNA (cfDNA) in maternal blood has a high sensitivity and specificity (1) , and literature suggests positive attitude and potential high uptake among pregnant women worldwide (2) (3) (4) (5) (6) (7) (8) (9) . However, ambivalence about implementation has been reported as the simple procedure of blood collection for cfDNA testing at no risk for the fetus leads to concerns about routinization of prenatal testing, undermining informed decision-making, increasing pressure from society to have the test and stigmatizing disabled persons in society (10) (11) (12) .
Traditionally, combined first-trimester screening (cFTS) for T21 has been based on a risk assessment including maternal age, thickness of the fetal nuchal translucency and levels of biochemical markers. Women at high risk have been offered invasive testing for prenatal diagnosis, but with a risk of miscarriage at 0.1-1% (13, 14) . The uptake of prenatal screening and diagnosis has differed between societies despite the apparent similarity in set-up of the screening program (15, 16) . This might reflect differences in society's attitude towards screening, i.e. how the offer is made available to women (private/public, free of charge/self-paid/insurance-dependent, profession of counselor), and in the individual's attitude (16) .
In general, a screening test must be acceptable to the individual and the attitude towards new technologies should preferably be investigated before implementation (17) . Uptake of prenatal screening and diagnosis is high in Denmark (> 90% and > 80%, respectively) compared with other countries (18) . The present public program is already broadly accepted and the role of cfDNA testing might not be as obvious as in other countries. In addition, the reported ambivalence surrounding cfDNA testing underlines the necessity of further investigation. Testing with cfDNA analysis can be implemented as a primary test or following conventional screening (secondary or contingent), and a positive cfDNA result should be followed by invasive testing (19) . The aim of our study was to investigate and compare the attitude towards cfDNA testing among unselected (before cFTS) and high-risk pregnant women. The attitude was defined as a woman's overall view, likely uptake and preferred strategy of prenatal testing.
Material and methods
The survey was conducted at the Center of Fetal Medicine, Copenhagen University Hospital Rigshospitalet, Denmark, and included two groups: unselected pregnant women (before cFTS) and women at high risk (≥ 1:300) of T21 following cFTS. Women who had not yet attended cFTS (unselected) were invited to participate by a link on the hospital website (opportunistic sampling) or invited on the phone. Women at high risk were invited following cFTS. Women were informed about cFTS by their general practitioner according to the national guidelines, and high-risk women were informed about the option of follow-up testing by a medical doctor or a specially trained midwife. Only women aged 18 years or more, with no language barrier were included. Reminders were sent at 2-week intervals.
We used a translated version of the questionnaire Antenatal testing for Down syndrome (3), which considers four domains: 1) factors impacting decision-making towards prenatal testing, 2) views on cfDNA testing, including service delivery and likely uptake, 3) scenarios asking people to place themselves in hypothetical antenatal situations, and 4) demographic characteristics. The first domain is measured by a five-point Likert scale. The other domains include questions to ascertain agreement, and single-or multiple-response questions. An introductory stem describes a hypothetical clinical case scenario including test specifications.
The questionnaire was translated into Danish, designed as an online survey (Enalyzer Survey Solution) and pretested (see Supplementary material, Appendix S1) (20) . At the time of this study, all high-risk women were offered invasive testing, and cfDNA testing was not offered through the public healthcare system.
Statistical analyses

SAS
â Enterprise Guide (SAS Institute, Cary, NC, USA)
was used for data analysis. Single-items were analyzed using descriptive statistics and a dichotomous index was yielded for questions on agreement by grouping the categories "Definitely yes" and "Probably yes", and "Definitely not" and "Probably not". The chi-squared test or Fisher's exact test was used as appropriate for intergroup comparisons of categorical data. Categories were grouped accordingly in case of few observations in a cell. McNemar's test was used to compare the likely uptake of follow-up testing following a high-risk assessment (cfDNA or invasive testing) and test decisions. A value of p < 0.05 was considered statistically significant. Only questionnaires with no missing data were included in the analysis.
Power calculation
The sample size calculations are based on likely uptake rates as an indirect measure of "attitude". To detect a significant increase in the likely uptake of follow-up testing (invasive testing or cfDNA testing) from 80% (18) to 88% (3), a total of at least 175 women should be included (80% power at a 5% significance level). To detect a 15% points difference in likely uptake of cfDNA testing between unselected and high-risk women, at least 44 women from each group should be included (4).
Ethical approval
The study was approved by the Data Protection Agency (03785/RH-2015-66). Ethical approval is not required for questionnaire studies performed in Denmark. 
Results
Unselected
Psychosocial factors impacting decision-making
For all women, the most important factor when deciding about antenatal testing for T21 on a scale from 1 ("Extremely important") to 5 ("Not at all important") was "My wish to have as much information as possible about the baby" with a mean score of 1.44, whereas the least important factors were related to religious beliefs ( Table 2) . The decision about antenatal testing for T21 was a joint decision between the woman and her partner for 87.5% of women in a relationship.
cfDNA testing: views and likely uptake
All high-risk women and 98.0% of unselected women considered cfDNA testing to be a positive development in antenatal care, and 97.2% of all responders would like to see cfDNA testing being offered (no significant difference between unselected and high-risk women, p = 0.712) ( Table 3 ). The women responded that cfDNA testing should be offered; 1) routinely to all women (40.3%), 2) to women identified as "high" risk through screening and in addition to women who request it, for example, "low" risk women who are still anxious (30.8%) or 3) only to women identified as "high" risk through screening (28.1%). "Safety of the baby" was the single most important factor for choosing cfDNA testing (59.7%). There was no significant difference between the responses of the unselected and high-risk groups.
In the hypothetical scenario where women should imagine themselves as being at high risk and offered cfDNA testing, 98.8% (250/253) would accept cfDNA testing including six women who, however, preferred invasive testing (no significant difference between risk groups, p = 0.386) ( Table 4) . With the possibility of giving two reasons, the majority responded that cfDNA testing would "help to make a decision about whether or not to continue the pregnancy" (85.8%). Second, with three reasons almost equally important, the women responded that they wanted "as much information about the baby as possible" (23.7%), "because there is no risk to the baby" (22.9%) and "to plan and prepare for the birth of a baby with Down syndrome" (21.7%).
There were no statistical differences between groups in preferred place of testing or test counselor, but a significant difference in how the test result should preferably be received (p = 0.001, Table 4 ).
Strategy comparison
Of women who would accept cFTS (n = 244, 96.4%) or were not sure (n = 4, 1.6%), 90.7% would accept invasive testing if at high risk (Table 5 ). In comparison, significantly more of these women would accept cfDNA testing (96.4%, McNemar's test, p = 0.009). Hence, the uptake of follow-up testing would increase significantly if cfDNA testing was offered as an alternative to invasive testing compared with invasive testing alone (98.8% vs. 90.7%, p < 0.001). Also, significantly more women would make their decision about cfDNA testing during the appointment rather than about invasive testing (92.3% vs. 56.1%, McNemar's test p < 0.001). The most frequent reason for declining invasive testing among accepters of cfDNA testing was "Because of the risk of miscarriage" (85.7%) followed by "I would not want to have to make a decision about whether to terminate the pregnancy" (35.7%). The two most frequent reasons why these women accepted cfDNA testing were "To plan and prepare for the birth of a child with Down syndrome" (64.3%) and "To help me make a decision about whether or not to continue with the pregnancy" (50.0%).
None of the women who accepted cfDNA testing only (n = 20) had had invasive testing in this or a previous pregnancy. In comparison, 19.3% of women who preferred invasive testing or would accept both tests had had invasive testing (n = 43, p = 0.03). Risk group, maternal age, education, ethnicity, religion, civil status, gestational age and knowing someone with a child with T21 were not statistically associated with acceptance of cfDNA testing only. Accepters of cfDNA testing only were significantly more likely to continue an affected pregnancy (30.0% vs. 3.6%) or have doubts about termination (50.0% vs. 32.1%) compared with accepters of both tests and those who preferred Scale from 1: "Extremely important" to 5: "Not at all important". 
Direct to consumer
The majority felt that cfDNA testing should not be available over the internet (63.6%), while 17.3% were not sure (Table 6 ). Significantly more high-risk women thought that cfDNA testing should be available over the internet (34.9% vs. 19.9%, p = 0.044) and would buy the test if they could afford it and it was not available through the public healthcare system (67.4% vs. 49.4%, p = 0.040). Women who were "Not sure" (n = 8) about the follow-up test were categorized as decliners of the test; "Not sure" for cfDNA testing and declining invasive test, n = 1 ("No test")/"Not sure" for invasive test and accepting cfDNA testing, n = 6 ("cfDNA testing")/"Not sure" for both tests, n = 1 ("No test"). Women who were 'Not sure' (n = 3) if they would make a decision about the test during the appointment were categorized as making the decision after the appointment; "Not sure" about invasive testing but making decision during appointment for cfDNA testing, n = 2/"Not sure" about invasive testing and making decision after the appointment for cfDNA testing, n = 1.
Discussion
This survey investigated the attitude towards screening for T21 with cfDNA testing among unselected and highrisk pregnant women in Denmark where cFTS is offered to all pregnant women, whereas cfDNA testing was not offered through the public healthcare system. We found an overwhelmingly positive attitude in both groups. Nearly all women considered cfDNA testing a positive development in antenatal care, and the likely uptake of follow-up testing would increase significantly if women at high risk were offered the choice of cfDNA testing as an alternative to invasive testing compared with invasive testing alone.
Our findings are in accordance with previous studies, including those of Lewis et al., who developed the questionnaire used in our study (3) (4) (5) (6) (7) (8) (9) . However, Lewis et al. reported how offering cfDNA testing would likely affect the uptake of the primary test (cFTS). In our population with uptake of cFTS above 90%, we compared the likely uptake of follow-up testing if cfDNA testing was offered as an alternative to invasive testing and found a significant increase from 90.7% to 98.8%. Two previous studies reported that women with an interest in cfDNA testing were more likely to terminate an affected pregnancy (3, 7) . In contrast, we found that women who would only accept follow up with cfDNA testing would be less likely to terminate or would have doubts compared with those "Definitely Yes" and "Probably Yes" have been pooled to "Yes". "Probably Not" and "Definitely Not" have been pooled to "No". a "Because it is possible", "I prefer the test through the public healthcare system but if they do not offer it to me, I would buy it myself", "Because of the busyness at the public hospitals" and "If I can get the result faster".
women who preferred invasive testing or accepted both tests (i.e. testing for "information only"). This was also reported in a recent cohort study (9) . Consequently, offering cfDNA testing following cFTS might not increase the termination rate of affected pregnancies. Instead, it provides the possibility to make a decision about the pregnancy at no risk of miscarriage, and reduce levels of anxiety if the high risk after cFTS was a false alarm or prepare for the birth of a child with T21 (2, 12, 21, 22) . Use of cfDNA testing for information only was previously reported to be associated with a religious belief, having or knowing someone with a child with T21, being < 35 years of age, having children, low educational level, not having screening, having had a low risk and not having invasive testing (3) . Except for the latter, we were not able to confirm these associations, possibly due to the low frequency of these characteristics among our participants, who all underwent cFTS. Danish decliners of cFTS share the characteristics of women who would use cfDNA testing for information only, which indicates that these women might accept cFTS if follow up with cfDNA testing was available (23) . In addition, women with another country of origin than Denmark were also less likely to accept cFTS, and it has been reported that non-white women are more likely to use cfDNA testing (3, 23) .
As in previous studies, women in our study reported that "Safety of the baby" was the single most important factor for cfDNA testing (3, 7, 8, 15) . In contrast, although health professionals favor test accuracy, cfDNA testing is more frequently preferred compared with invasive testing or no test (15) . Significantly more women would decide about cfDNA testing during the counseling than about invasive testing, suggesting that the risk of miscarriage demands more thorough deliberation, and avoiding this risk at the cost of test accuracy is preferred by most women (15, 24) . Interestingly, the majority of women in our study (89.0%) stated that the wish to have as much information as possible about the baby was the most important factor when deciding about antenatal testing in general, whereas "not wanting to risk the safety of my baby" was ranked as seventh most important (of 18 statements). Accordingly, women would pay more for a higher level of information than for a decrease in miscarriage risk in a Dutch study (24) . The highest level of information about the baby would be obtained only by invasive testing (i.e. karyotyping, chromosomal microarray or, ultimately, by whole exome or genome sequencing). As in the original questionnaire, participants in our survey were informed that the procedure-related miscarriage risk with invasive testing was about 1%. However, a recent study reports that this risk is minimal (14) . In addition, our survey included testing for T21 only and the cfDNA test specifications did not inform about time to result, expected failure rate and the risk of ambiguous test results, which might have decreased likely uptake of cfDNA testing. Health professionals should be aware of differences in preferences of test characteristics when counseling women, and both up-to-date benefits and limitations should be addressed thoroughly to promote informed decision-making (25) (26) (27) . Also, the option of not testing should be highlighted to women.
Most women thought that cfDNA testing should not be available over the internet, but significantly more high-risk women would buy it online if the test was not offered through the public healthcare system. In Denmark, cfDNA testing is now being offered through the public healthcare system to women at high risk as an alternative to invasive testing -the ideal strategy for only 28.1% of the women in our study. Like others (2, 3, 12, 22) , the majority thought that cfDNA testing should be offered more liberally. "Routinization", i.e. the need for less time to decide about cfDNA testing and the likely high uptake of testing, might lead to societal pressure on the individual to undergo testing and eventually termination, in addition to concern about informed decision-making (10, 12) . For society, questions of stigmatizing disabled persons arises (12) . In our study, the quality of life of a child with T21, the available support for people with T21 and the impact on the disabled community of fewer people with T21 being born were considered important to 81.9%, 52.1% and 11.0% of women, respectively.
Strengths and limitations
This is the first study to report attitude toward cfDNA testing and likely uptake among women in Denmark with uptake of cFTS > 90%. The survey is based on hypothetical scenarios, but the potential "hypothetical bias" is limited as the participating women are the targets of the tests in question, so are presumed to recognize and relate to the clinical situation. The overwhelmingly positive attitude toward cfDNA testing reported previously and in this study might be caused by the inefficiency of quantitative survey studies to "detect" the ambivalence reported in qualitative studies, and is therefore only detecting the positive "first response" (28) . However, we cannot exclude that a study including a larger sample size might detect differences in attitude between the groups.
The response rate in the study was high, but we are unable to report on characteristics of the non-responders with a risk of selection bias. The survey was performed in an urban area with mainly Caucasian and well-educated responders, which may limit generalizability. Also, women with a language barrier were not included and ethnic differences in knowledge and uptake of prenatal testing might introduce a "health gap" (29, 30) .
Validated instruments to assess attitude towards prenatal testing are missing. Our survey is based on a questionnaire developed by Lewis et al. and was formally translated (3, 20) . The questionnaire is based on qualitative research within the area, developed under review of an expert research group and pilot-tested, which claims content validity. Each item in the instrument focuses on a single construct, which makes construct validity and reliability indeterminable (3) . However, the instrument has now been applied to a different population and produced consistent results. In addition, the results correspond to those of other surveys, suggesting that the items measure the expected constructs.
Conclusion
The view towards cfDNA testing for T21 was overwhelmingly positive among both unselected and high-risk pregnant women. Most women supported a liberal offer of cfDNA testing and significantly more high-risk women would buy it if it was not offered through the public healthcare system. The uptake of follow-up testing would likely increase if cfDNA testing was offered as an alternative to invasive testing. However, the women who would only accept follow-up with cfDNA testing were less likely to terminate an affected pregnancy, implying that the termination rate would not increase correspondingly. Our findings highlight awareness of informed decision-making and attention to avoid routinization.
